The University of Chicago Header Logo

Connection

Matthew Koshy to Middle Aged

Back to Details
This is a "connection" page, showing publications Matthew Koshy has written about Middle Aged.
Matthew Koshy
Connection Strength
1.217
Middle Aged
  1. Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. Lung Cancer. 2019 04; 130:162-168.
    View in: PubMed
    Score: 0.037
  2. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol. 2019 Jan 28; 14(1):18.
    View in: PubMed
    Score: 0.037
  3. Survival outcomes for postoperative chemoradiation in intermediate-risk oral tongue cancers. Head Neck. 2017 12; 39(12):2537-2548.
    View in: PubMed
    Score: 0.034
  4. Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neurooncol. 2017 Dec; 135(3):529-534.
    View in: PubMed
    Score: 0.034
  5. Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg. 2017 07 01; 143(7):691-699.
    View in: PubMed
    Score: 0.033
  6. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer. 2017 06; 108:222-227.
    View in: PubMed
    Score: 0.033
  7. Impact of fraction size on locally advanced oropharyngeal and nasopharyngeal cancers treated with chemoradiation. Oral Oncol. 2017 05; 68:27-35.
    View in: PubMed
    Score: 0.033
  8. National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma. Cancer. 2017 01 01; 123(2):273-282.
    View in: PubMed
    Score: 0.032
  9. Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era. JAMA Otolaryngol Head Neck Surg. 2016 08 01; 142(8):777-88.
    View in: PubMed
    Score: 0.031
  10. Patterns of care and survival outcomes examining radiation therapy for advanced Hodgkin lymphoma. Leuk Lymphoma. 2017 02; 58(2):343-347.
    View in: PubMed
    Score: 0.031
  11. The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. Am J Clin Oncol. 2016 Apr; 39(2):136-41.
    View in: PubMed
    Score: 0.031
  12. Improved survival time trends in Hodgkin's lymphoma. Cancer Med. 2016 06; 5(6):997-1003.
    View in: PubMed
    Score: 0.030
  13. Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis. Oral Oncol. 2016 Mar; 54:58-67.
    View in: PubMed
    Score: 0.030
  14. Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. J Natl Cancer Inst. 2015 Dec; 107(12):djv278.
    View in: PubMed
    Score: 0.029
  15. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer. Pract Radiat Oncol. 2015 Nov-Dec; 5(6):374-82.
    View in: PubMed
    Score: 0.029
  16. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
    View in: PubMed
    Score: 0.028
  17. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
    View in: PubMed
    Score: 0.028
  18. Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis. J Thorac Oncol. 2015 Feb; 10(2):264-71.
    View in: PubMed
    Score: 0.028
  19. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):344-50.
    View in: PubMed
    Score: 0.028
  20. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. Cancer Med. 2015 Apr; 4(4):513-8.
    View in: PubMed
    Score: 0.028
  21. Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I non-small cell lung cancer. Radiother Oncol. 2015 Feb; 114(2):148-54.
    View in: PubMed
    Score: 0.028
  22. The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. Clin Lung Cancer. 2014 Sep; 15(5):365-71.
    View in: PubMed
    Score: 0.027
  23. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol. 2014 Apr; 117(2):321-7.
    View in: PubMed
    Score: 0.026
  24. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. PLoS One. 2014; 9(1):e82642.
    View in: PubMed
    Score: 0.026
  25. Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy. PLoS One. 2013; 8(9):e75336.
    View in: PubMed
    Score: 0.026
  26. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013 Jul; 8(7):915-22.
    View in: PubMed
    Score: 0.025
  27. An analysis of patient characteristics and clinical outcomes in primary pulmonary sarcoma. J Thorac Oncol. 2013 Feb; 8(2):147-51.
    View in: PubMed
    Score: 0.024
  28. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
    View in: PubMed
    Score: 0.022
  29. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns. Am J Clin Oncol. 2011 Jun; 34(3):259-64.
    View in: PubMed
    Score: 0.022
  30. Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):619-25.
    View in: PubMed
    Score: 0.021
  31. Impact of neoadjuvant radiation on survival in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1388-94.
    View in: PubMed
    Score: 0.020
  32. Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):203-9.
    View in: PubMed
    Score: 0.019
  33. Primary MALT lymphoma of the gallbladder. Case report. J Gastrointestin Liver Dis. 2008 Jun; 17(2):207-10.
    View in: PubMed
    Score: 0.018
  34. Stereotactic Body Radiation Therapy Facilitating Debulking Surgery in Metastatic VIPoma with Severe Diarrhea and Hypovolemic Shock. Am J Case Rep. 2025 Sep 06; 26:e949041.
    View in: PubMed
    Score: 0.015
  35. Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study. Haematologica. 2026 Jan 01; 111(1):177-183.
    View in: PubMed
    Score: 0.014
  36. Limited survival benefit in patients diagnosed with glioblastoma post-2016: a SEER population based registry analysis. J Cancer Res Clin Oncol. 2025 Jun 02; 151(6):179.
    View in: PubMed
    Score: 0.014
  37. High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT). Eur J Haematol. 2024 Jul; 113(1):110-116.
    View in: PubMed
    Score: 0.013
  38. Brain arteriovenous malformation flow after stereotactic radiosurgery: Role of quantitative MRA. Interv Neuroradiol. 2024 Apr; 30(2):242-249.
    View in: PubMed
    Score: 0.012
  39. Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Netw Open. 2022 04 01; 5(4):e227240.
    View in: PubMed
    Score: 0.012
  40. Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria. Chest. 2022 01; 161(1):248-256.
    View in: PubMed
    Score: 0.011
  41. Patterns of Care and Survival Outcomes for Odontogenic Cancers. Laryngoscope. 2021 05; 131(5):E1496-E1502.
    View in: PubMed
    Score: 0.010
  42. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities. J Thorac Oncol. 2020 11; 15(11):1738-1747.
    View in: PubMed
    Score: 0.010
  43. Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial. JAMA Oncol. 2018 09 01; 4(9):1291-1293.
    View in: PubMed
    Score: 0.009
  44. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. Ann Surg Oncol. 2018 Jul; 25(7):2018-2026.
    View in: PubMed
    Score: 0.009
  45. Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1759-1765.
    View in: PubMed
    Score: 0.009
  46. Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 01; 36(7):642-651.
    View in: PubMed
    Score: 0.009
  47. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200?mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2018 07; 59(7):1666-1671.
    View in: PubMed
    Score: 0.008
  48. Effect of Endoscopic Bronchial Ultrasound on Outcomes for Stage I Non-Small-Cell Lung Cancer Patients Receiving Hypofractionated Radiotherapy. Clin Lung Cancer. 2018 03; 19(2):e227-e233.
    View in: PubMed
    Score: 0.008
  49. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer. 2017 Sep 01; 123(17):3402-3409.
    View in: PubMed
    Score: 0.008
  50. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol. 2017 07; 124(1):139-146.
    View in: PubMed
    Score: 0.008
  51. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer. 2017 Jul 15; 123(14):2762-2772.
    View in: PubMed
    Score: 0.008
  52. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol. 2017 04; 12(4):734-744.
    View in: PubMed
    Score: 0.008
  53. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. J Otolaryngol Head Neck Surg. 2016 Nov 24; 45(1):62.
    View in: PubMed
    Score: 0.008
  54. Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy. Technol Cancer Res Treat. 2017 02; 16(1):15-21.
    View in: PubMed
    Score: 0.008
  55. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42.
    View in: PubMed
    Score: 0.008
  56. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 2016 Mar; 22(3):441-8.
    View in: PubMed
    Score: 0.007
  57. Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):968-75.
    View in: PubMed
    Score: 0.007
  58. Changes in brachytherapy-based APBI patient selection immediately before and after publication of the ASTRO consensus statement. Brachytherapy. 2015 Jul-Aug; 14(4):490-5.
    View in: PubMed
    Score: 0.007
  59. Variation in insurance status by patient demographics and tumor site among nonelderly adult patients with cancer. Cancer. 2015 Jun 15; 121(12):2020-8.
    View in: PubMed
    Score: 0.007
  60. Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2034-41.
    View in: PubMed
    Score: 0.007
  61. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol. 2014 Oct 01; 32(28):3118-25.
    View in: PubMed
    Score: 0.007
  62. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
    View in: PubMed
    Score: 0.007
  63. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014 Mar-Apr; 13(2):157-62.
    View in: PubMed
    Score: 0.006
  64. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol. 2013 May; 20(5):1436-43.
    View in: PubMed
    Score: 0.006
  65. Squamous cell carcinoma of the esophagus: treat with how many modalities? Semin Oncol. 2009 Dec; 36(6):493-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.